

AD _____

Award Number: DAMD17-02-1-0147

TITLE: Inhibitory Ah Receptor - Androgen Receptor Crosstalk in
Prostate Cancer

PRINCIPAL INVESTIGATOR: Stephen Safe, Ph.D.

CONTRACTING ORGANIZATION: Texas A&M Research Foundation
College Station, Texas 77843-3578

REPORT DATE: February 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030701 188

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE February 2003	3. REPORT TYPE AND DATES COVERED Annual (15 Jan 02 - 15 Jan 03)	
4. TITLE AND SUBTITLE Inhibitory Ah Receptor - Androgen Receptor Crosstalk in Prostate Cancer			5. FUNDING NUMBERS DAMD17-02-1-0147	
6. AUTHOR(S) : Stephen Safe, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Texas A&M Research Foundation College Station, Texas 77843-3578 E-Mail: ssafe@cvm.tamu.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. Abstract (Maximum 200 Words) <i>(abstract should contain no proprietary or confidential information)</i> Treatment for prostate cancer depends on multiple factors including the stage of the tumor and expression of the androgen receptor (AR). Endocrine therapy can be used for treatment of early stage androgen-responsive tumors, whereas chemotherapy for later stage androgen-nonresponsive tumors is problematic. We have investigated the aryl hydrocarbon receptor (AhR) as a potential target for treating prostate cancer using a new series of relatively non-toxic selective AhR modulators (SAhRMs). Initial studies show that 22RV1, PC3 and LNCaP prostate cancer are Ah-responsive and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1-dependent activities in all three cell lines. Moreover, two SAhRMs, namely diindolylmethane (DIM) and 6-methyl-1,3,8-trichlorodibenzofuran (6-MCDF) inhibit growth of AR-positive 22RV1 and AR-negative PC3 prostate cancer cells. In addition, AhR ligands inhibit dihydrotestosterone-induced upregulation of AR protein in 22RV1 cells suggesting a possible mechanism for inhibitory AhR-AR crosstalk. The growth inhibitory effects of SAhRMs in PC3 cells suggests that AhR ligands also inhibit growth of androgen-nonresponsive cells.				
14. SUBJECT TERMS: prostate cancer			15. NUMBER OF PAGES 26	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover	1
SF 298	2
Introduction.....	4
Body	5
Key Research Accomplishments	10
Reportable Outcomes	10
Conclusions	10
References	11
Appendix	18

INTRODUCTION

Prostate cancer is the most commonly diagnosed cancer in North American men and it is estimated that there are over 300,000 newly diagnosed cases each year (1, 2). The incidence and mortality rates from prostate cancer are increasing and this is due, in part, to an increasingly aging population and the higher incidence of this disease in older men (3, 4). Prostate cancer therapy is dependent on the stage of the tumor and AR expression. Early stage androgen-responsive prostate cancers can be treated by castration or with antiandrogens or drugs that block androgen-induced responses including steroidal antiandrogens (cyproterone), LHRH analogs, nonsteroidal antiandrogens (flutamide, nilutamide, bicalutamide), and the potent estrogenic drug diethylstilbestrol (reviewed in 5-8). In addition, there are several novel strategies for treatment of prostate cancer and other tumor-types and these include targeting of critical genes involved in tumor cell growth and metastasis (e.g. antiangiogenic drugs, antisense therapy) (9-13). Ligands for nuclear receptors (NR) are also being developed for treatment of prostate cancer through inhibitory NR-AR crosstalk that involves various compounds that bind the retinoid acid/X-receptors (retinoids), vitamin D receptor (calcitrol), and peroxisome proliferator activate receptor γ (troglitazone) (14-26). A recent study in androgen-responsive LNCaP prostate cancer cells showed that 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD), a ligand for the aryl hydrocarbon receptor (AhR), inhibited testosterone-induced cell proliferation and gene/reporter gene expression (27). We have developed a series of alternate-substituted (2,3,6,8- and 2,4,6,8-) alkyl polychlorinated dibenzofurans (PCDFs) and substituted diindolymethanes (DIMs) (Fig. 1) that inhibit rodent mammary tumor growth *in vivo*, but do not induce toxic responses

associated with exposures to TCDD (28-35). These selective AhR modulators (SAhRMs) are therefore an important new class of drugs that target the AhR and they have been successfully used for inhibiting growth of breast tumors/cells (28-35) and pancreatic cancer cells (36). Studies sponsored by this grant are focused on inhibitory AhR-AR crosstalk in human prostate cancer cells and applications of SAhRMs for treatment of this disease. These studies will include characterization of the Ah-responsiveness of several prostate cancer cells, inhibition of prostate cancer cell growth by SAhRMs, mechanisms of inhibitory AhR-AR crosstalk and *in vivo* inhibition of prostate tumor growth by SAhRMs in athymic nude mice bearing prostate cancer cell xenografts.




Figure 1. TCDD and selective AhR modulators (SAhRMs) 6-MCDF and DIM.

BODY

Characterization of Ah-responsiveness of prostate cancer cells

The first part of this project (Task 1) has been focusing on characterization of Ah-responsiveness of several prostate cancer cell lines by determining induction of CYP1A1-dependent activities by TCDD and by SAhRMs. The results in Figure 2 summarize the concentration-dependent induction of ethoxyresorufin O-deethylase (EROD) activity by TCDD (note: this activity is catalyzed by CYP1A1). TCDD clearly

induces EROD activity in 22RV1 prostate cancer cells at concentrations of 0.1, 1.0 and 10.0 nM (Fig. 2A); the EC₅₀ value is < 0.1 nM and a > 14-fold induction response was observed. In a parallel experiment, DIM exhibited minimal induction of EROD activity (Fig. 2B), and this is consistent with previous reports showing that DIM is a weak AhR agonist/partial antagonist for this response.




Figure 2. Induction of CYP1A1-dependent EROD activity by DIM and TCDD in 22RV1 prostate cancer cells.

The induction of EROD activity by TCDD and DIM in PC3 prostate cancer cells was also investigated using serum-free medium. The results after treatment for 24 h showed that 10 nM TCDD and both 1 and 10 μ M DIM induced EROD activity (< 3-fold) (Fig. 3). In contrast, 1 nM TCDD was not active. The experiments were therefore extended for 48, 72 and 96 h, and the results showed the novel effects of prolonged treatment with TCDD or DIM on induction of EROD activity. The lower concentrations of TCDD (1 nM) and DIM (1 μ M) were not inducers at the longer time periods, and the induction response by 10 μ M DIM was similar at all time points. In contrast, prolonged treatment with 10 nM TCDD increased induction of EROD activity and after 96 h, there

was a > 29-fold induction response. These results demonstrate that the AhR is functional in PC3 prostate cancer cells; however, optimal responsiveness is observed only after 96 h and the reason for this unusual temporal pattern of Ah-responsiveness is currently being investigated. Previous studies have demonstrated that LNCaP prostate cancer cells are also Ah-responsive, and this was also observed in our studies which show that TCDD induced luciferase activity in cells transfected with a construct containing three tandem dioxin response elements linked to a luciferase reporter gene (pDRE₃) (data not shown).




Figure 3. Induction of EROD activity by DIM and TCDD in PC3 prostate cancer cells. Cells were seeded 50,000 per well in 48-well plates in DME + 5% stripped serum and allowed to attach 24 h. Cells were then treated with DMSO vehicle or treatments in DMSO one time in DME-F12 media without serum supplementation, with 7 or 8 wells per treatment group. On separate plates, the EROD assay was performed after 24, 48, 72 or 96 h.

Inhibition of prostate cancer cell growth by SAhRMs

Results of preliminary studies presented in this grant proposal showed that TCDD inhibited growth of prostate cancer cells. Another objective of Task 1 was to further investigate the effects of SAhRMs on growth of prostate cancer cells, and the results indicate that DIM inhibits growth of PC3 cells in serum-free or 1% serum-

containing medium at concentrations as low as 0.1 μM DIM (Fig. 4). Similar results were obtained for both DIM and 6-methyl-1,3,8-trichlorodibenzofuran (6-MCDF) in 22RV1 cells (Fig. 5) and demonstrate that both classes of SAhRMs inhibit growth of prostate cancer cells.




Figure 4. Inhibition of PC3 prostate cancer cell growth by DIM. Cells (10^5) were seeded in 6-well plates and treated with different concentrations of DIM for 6 days. Significant ($p < 0.05$) inhibition of cell growth is indicated by an asterisk and results are presented at means \pm SE for at least three replicate determinations.




Figure 5. Inhibition of 22RV1 cell growth by 6-MCDF and DIM. Cells were essentially treated as described for PC3 cells (Fig. 4) and significant ($p < 0.05$) induction is indicated by an asterisk.

Effects of TCDD, dihydrotestosterone (DHT) and E2 on AR levels

The AR is expressed in 22RV1 prostate cancer cells, and we have investigated the time-dependent effects of DHT, 17β -estradiol (E2), TCDD, E2 plus TCDD, and DHT plus TCDD on AR protein expression in this cell line (Task 2). Ligands for several receptors initiate degradation of their cognate receptors (37-46); for example, estrogens, retinoids and progestins trigger proteasome-dependent ER, RXR/RAR and PR protein downregulation. One report showed that androgens do not induce downregulation of AR protein in LNCaP cells (47); however, in untreated cells, the proteasome inhibitor MG132 enhanced AR protein levels in the same cell line. TCDD

and SAhRMs induce proteasome-dependent degradation of the AhR and ER α in breast cancer cells (48), and we therefore investigated inhibitory AhR-AR crosstalk on AR protein expression. The results in Figure 6 demonstrate that 10 nM DHT induces a time-dependent > 3.5-fold increase in AR protein expression over a treatment period of 24 h, whereas 10 nM E2 or TCDD alone (or in combination) had no effect on AR protein levels. In 22RV1 cells cotreated with TCDD plus DHT, the increased expression observed with DHT alone was repressed by TCDD. Similar results were observed in LNCaP cells (data not shown), and current studies are focused on the role of this response in mediating inhibitory AhR-AR crosstalk in prostate cancer cells.




Figure 6. Effects of DHT, E2, TCDD and their combination on AR protein expression on 22RV1 cells. Results are expressed as means \pm SD for at least three replicate determinations.

KEY RESEARCH ACCOMPLISHMENTS

- 22RV1 prostate cancer cells have been identified as Ah-responsive.
- PC3 prostate cancer cells are also Ah-responsive but this is dependent on a lag time for activation of CYP1A1-dependent activity.
- SAhRMs inhibit growth of both 22RV1 and PC3 prostate cancer cells.
- DHT induces upregulation of AR protein in 22RV1 and LNCaP cells.
- E2 and TCDD do not affect AR protein expression in 22RV1 cells.
- TCDD partially blocks DHT-dependent upregulation of AR protein in 22RV1 cells.

REPORTABLE OUTCOMES

Safe, S. and McDougal, A. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers. *Int. J. Oncol.* 20:1123-1128, 2002.

Morrow, D., McDougal, A. and Safe, S. Comparative aryl hydrocarbon receptor-hormone receptor crosstalk in breast and prostate cancer cells. Society of Toxicology Annual Meeting, Nashville, TN. March, 2002.

CONCLUSIONS

Initial studies have demonstrated that PC3, 22RV1 and LNCaP prostate cancer cells are Ah-responsive, and SAhRMs inhibit growth of these cells. TCDD inhibits DHT-induced AR protein expression in these cells, and the role of this inhibitory AhR-AR interaction will be further investigated in the proposed studies. Future work will focus on

critical genes/proteins associated with growth of prostate cancer cells and determine those that are specifically targeted for inactivation by the AhR.

REFERENCES

1. Landis, S.H., Murray, T., Bolden, S., and Wingo, P.A. Cancer statistics. *CA. Cancer J. Clin.* 48:6-29, 1998.
2. Shibata, A., Ma, J., and Whittemore, A.S. Prostate cancer incidence and mortality in the United States and the United Kingdom. *J. Natl. Cancer Inst.* 90:1230-1231, 1998.
3. Gao, X., Porter, A.T., Grignon, D.J., Pontes, J.E., and Honn, K.V. Diagnostic and prognostic markers for human prostate cancer. *Prostate* 31:264-281, 1997.
4. Chiarodo, A. National Cancer Institute roundtable on prostate cancer: future research directions. *Cancer Res.* 51:2498-2505, 1991.
5. Sadar, M.D., Hussain, M., and Bruchofsky, N. Prostate cancer: molecular biology of early progression to androgen independence. *Endocr. Relat. Cancer* 6:487-502, 1999.
6. Klotz, L. Hormone therapy for patients with prostate carcinoma. *Cancer* 88:3009-3014, 2000.
7. Morris, M.J. and Scher, H.I. Novel strategies and therapeutics for the treatment of prostate carcinoma. *Cancer* 89:1329-1348, 2000.
8. Boccardo, F. Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy? *Crit. Rev. Oncol. Hematol.* 35:121-132, 2000.

9. Boasberg, P., Harbaugh, J., Eisenberger, M., Harris, J., Langleben, A., and Ahmann, F. Marimastat in patients with hormone refractory prostate cancer: a dose-finding study. *Proc. Am. Soc. Clin. Oncol.* 16:1126-1997. (Abstract)
10. Knox, J.D., Bretton, L., Lynch, T., Bowden, G.T., and Nagle, R.B. Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. *Prostate* 35:248-254, 1998.
11. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., and Fujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. *Cancer Res.* 53:5233-5236, 1993.
12. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat. Med.* 1:27-31, 1995.
13. Folkman, J. Tumor angiogenesis: therapeutic implications. *N. Engl. J. Med.* 285:1182-1186, 1971.
14. Dorai, T., Olsson, C.A., Katz, A.E., and Buttyan, R. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. *Prostate* 32:246-258, 1997.
15. Pienta, K.J., Nguyen, N.M., and Lehr, J.E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. *Cancer Res.* 53:224-226, 1993.
16. Pollard, M., Luckert, P.H., and Sporn, M.B. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. *Cancer Res.* 51:3610-3611, 1991.

17. Kelly, W.K., Curley, T., Liebertz, C., Kim, B., and Scher, H.I. Phase II trial of 13-cis-retinoic acid and interferon- α 2a in patients with adenocarcinoma of the prostate. *Proc. Am. Soc. Clin. Oncol.* 15:2501996. (Abstract)
18. Miller, G.J., Stapleton, G.E., Ferrara, J.A., Lucia, M.S., Pfister, Hedlund, T.E., and Upadhy, P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 α ,25-dihydroxyvitamin D3. *Cancer Res.* 52:515-520, 1992.
19. Miller, G.J., Stapleton, G.E., Hedlund, T.E., and Moffat, K.A. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1 α ,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. *Clin. Cancer Res.* 1:997-1003, 1995.
20. Peehl, D.M., Skowronski, R.J., Leung, G.K., Wong, S.T., Stamey, T.A., and Feldman, D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. *Cancer Res.* 54:805-810, 1994.
21. Gross, C., Stamey, T., Hancock, S., and Feldman, D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). *J. Urol.* 159:2035-2039, 1998.
22. Kubota, T., Koshizuka, K., Williamson, E.A., Asou, H., Said, J.W., Holden, S., Miyoshi, I., and Koeffler, H.P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both *in vitro* and *in vivo*. *Cancer Res.* 58:3344-3352, 1998.
23. Tontonoz, P., Singer, S., Forman, B.M., Sarraf, P., Fletcher, J.A., Fletcher, C.D., Brun, R.P., Mueller, E., Altiock, S., Oppenheim, H., Evans, R.M., and Spiegelman,

- B.M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. *Proc. Natl. Acad. Sci. USA* 94:237-241, 1997.
24. Tontonoz, P., Hu, E., and Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. *Cell* 79:1147-1156, 1994.
25. Mueller, E., Sarraf, P., Tontonoz, P., Evans, RM, Martin, K.J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B.M. Terminal differentiation of human breast cancer through PPAR γ . *Mol. Cell* 1:465-470, 1998.
26. Smith, M., Mueller, E., Demetri, G., Kaufman, D., Oh, W., and Jacobsen, J. Preliminary results: phase II trial of troglitazone for androgen-dependent (AD) and androgen-independent (AI) prostate cancer. *Proc. Am. Soc. Clin. Oncol.* 18:3281999. (Abstract)
27. Jana, N.R., Sarkar, S., Ishizuka, M., Yonemoto, J., Tohyama, C., and Sone, H. Cross-talk between 2,3,7,8-tetrachlorodibenzo-*p*-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. *Biochem. Biophys. Res. Commun.* 256:462-468, 1999.
28. Safe, S., Qin, C., and McDougal, A. Development of selective aryl hydrocarbon receptor modulators (SARMs) for treatment of breast cancer. *Expert Opinion on Investigational Drugs* 8:1385-1396, 1999.
29. Dickerson, R., Howie-Keller, L., and Safe, S. Alkyl polychlorinated dibenzofurans and related compounds as antiestrogens in the female rat uterus: structure-activity studies. *Toxicol. Appl. Pharmacol.* 135:287-298, 1995.

30. McDougal, A., Wilson, C., and Safe, S. Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. *Cancer Lett.* 120:53-63, 1997.
31. McDougal, A. Aromatic Hydrocarbon Receptor-Based Antiestrogens as Treatments for Breast Cancer. Texas A&M University. Thesis/Dissertation. 2000.
32. Safe, S., Wargovich, M.J., Lamartinierre, C.A., and Mukhtar, H. Symposium on mechanism of action of naturally-occurring anticarcinogens. *Toxicol. Sci.* 5:1-8, 1999.
33. McDougal, A., Gupta, M.S., Morrow, D., Ramamoorthy, K., Lee, Y.-E., and Safe, S. Methyl-substituted diindolylmethanes as inhibitors of estrogen-induced growth of T47D cells and mammary tumors in rats. *Breast Cancer Res. Treat.* 66:147-157, 2001.
34. Chen, I., McDougal, A., Wang, F., and Safe, S. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. *Carcinogenesis* 19:1631-1639, 1998.
35. McDougal, A., Sethi-Gupta, M., Ramamoorthy, K., Sun, G., and Safe, S. Inhibition of carcinogen-induced rat mammary tumor growth and other estrogen-dependent responses by symmetrical dihalo-substituted analogs of diindolylmethane. *Cancer Letts.* 151:169-179, 2000.
36. Koliopanus, A., Kleeff, J., Xiao, Y., Safe, S., Zimmerman, A., Buchler, M.W., and Friess, H. Increased aryl hydrocarbon receptor expression offers a potential therapeutic target in pancreatic cancer. *Oncogene* 2002. (in press)

37. Alarid, E.T., Bakopoulos, N., and Solodin, N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. *Mol. Endocrinol.* 13:1522-1534, 1999.
38. Nawaz, Z., Lonard, D.M., Dennis, A.P., Smith, C.L., and O'Malley, B.W. Proteasome-dependent degradation of the human estrogen receptor. *Proc. Natl. Acad. Sci. USA* 96:1858-1862, 1999.
39. El Khissiin, A. and Leclercq, G. Implication of proteasome in estrogen receptor degradation. *FEBS Lett.* 448:160-166, 1999.
40. Lonard, D.M., Nawaz, Z., Smith, C.L., and O'Malley, B.W. The 26S proteasome is required for estrogen receptor- α and coactivator turnover and for efficient estrogen receptor- α transactivation. *Mol. Cell* 5:939-948, 2000.
41. Roberts, B.J. and Whitelaw, M.L. Degradation of the basic helix-loop-helix/Per-ARNT-Sim homology domain dioxin receptor via the ubiquitin/proteasome pathway. *J. Biol. Chem.* 274:36351-36356, 1999.
42. Davarinos, N.A. and Pollenz, R.S. Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytoplasmic proteasome following nuclear export. *J. Biol. Chem.* 274:28708-28715, 1999.
43. Ma, Q. and Baldwin, K.T. 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin-induced degradation of aryl hydrocarbon receptor (AhR) by the ubiquitin-proteasome pathway. Role of the transcription activator and DNA binding of AhR. *J. Biol. Chem.* 275:8432-8438, 2000.

44. Boudjelal, M., Wang, Z., Voorhees, J.J., and Fisher, G.J. Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor γ and retinoid X receptor α in human keratinocytes. *Cancer Res.* 60:2247-2252, 2000.
45. Kopf, E., Plassat, J.-L., Vivat, V., de Thé, H., Chambon, P., and Rochette-Egly, C. Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors α and γ through the ubiquitin-proteasome pathway. *J. Biol. Chem.* 275:33280-33288, 2000.
46. Dace, A., Zhao, L., Park, K.S., Furuno, T., Takamura, N., Nakanishi, M., West, B.L., Hanover, J.A., and Cheng, S. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. *Proc. Natl. Acad. Sci. USA* 97:8985-8990, 2000.
47. Sheflin, L., Keegan, B., Zhang, W., and Spaulding, S.W. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. *Biochem. Biophys. Res. Commun.* 275:144-150, 2000.
48. Wormke, M., Stoner, M., Saville, B., and Safe, S. Crosstalk between estrogen receptor α and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. *FEBS Lett.* 478:109-112, 2000.

APPENDIX

1. Safe, S. and McDougal, A. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers. *Int. J. Oncol.* 20:1123-1128, 2002.

2. Morrow, D., McDougal, A. and Safe, S. Comparative aryl hydrocarbon receptor-hormone receptor crosstalk in breast and prostate cancer cells. Society of Toxicology Annual Meeting, Nashville, TN. March, 2002.

Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review)

STEPHEN SAFE and ANDREW McDOUGAL

Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843-4466, USA

Received February 18, 2002; Accepted March 30, 2002

Abstract. Ligand-activated receptors are extensively used as targets for developing tissue-selective drugs for treatment of multiple diseases including cancers. The aryl hydrocarbon receptor (AhR) is a basic helix-loop-helix transcription factor that binds both synthetic chemicals such as 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) and naturally-occurring phytochemicals, sterols and heme breakdown products. The high affinity ligand TCDD induces several AhR-mediated changes in gene expression, tissue/species-specific toxicities, and both tumorigenic and anticarcinogenic responses including inhibition of estrogen-dependent mammary and uterine tumor formation and growth. Research in this laboratory has demonstrated that TCDD inhibits E2-induced responses in the rodent uterus and mammary tumors (growth inhibition) and in breast and endometrial cancer cell lines through complex inhibitory AhR-estrogen receptor (ER) crosstalk. 6-Alkyl-1,3,8-trichlorodibenzofurans and substituted diindolylmethanes represent two structural classes of selective AhR modulators (SAhRMs). These compounds are relatively non-toxic and inhibit ER-positive and ER-negative mammary tumor growth, and synergize with tamoxifen to inhibit breast cancer growth and block tamoxifen-induced estrogenic activity in the uterus. Preliminary studies also indicate that SAhRMs inhibit prostate cancer cell growth, and there is evidence for inhibitory AhR-androgen receptor crosstalk. SAhRMs represent a novel class of drugs for treatment of hormone-dependent cancers, and combined therapies of SAhRMs with tamoxifen and other selective ER modulators (SERMs) provides a new approach for treating women with breast cancer.

Contents

1. Introduction
2. Inhibitory AhR-ER α crosstalk: *in vivo*
3. Inhibitory AhR-ER α crosstalk: *in vitro*
4. Mechanisms of AhR-ER crosstalk
5. Selective AhR modulators (SAhRMs) for treatment of ER-positive breast cancer
6. SAhRMs for treatment of ER-negative breast cancer
7. Potential applications of SAhRMs for treating other cancers
8. Summary

1. Introduction

The aryl hydrocarbon receptor (AhR) is a member of the basic helix-loop-helix family of nuclear transcription factors, and this receptor was initially identified by its high affinity binding to the environmental toxicant, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) (1,2). TCDD and structurally-related halogenated aromatics modulate expression of multiple genes which play a role in the species-, sex- and age-specific toxic, genotoxic and anticarcinogenic responses associated with exposure of laboratory animals to these compounds (2-6). The endogenous ligand for the AhR is unknown; however, several reports have now demonstrated that this receptor binds structurally-diverse synthetic chemicals as well as aromatic amines in cooked foods, phytochemicals including indole-3-carbinol (I3C) and related indole-derived compounds, carotenoids, flavonoids, steroidal compounds, and bilirubin (Fig. 1) (7-14). Interestingly, steroid hormone receptors and other ligand-activated nuclear receptors also bind different structural classes of chemicals and many of these receptors are targets for developing drugs that selectively ameliorate one or more receptor-mediated responses. For example, selective estrogen receptor (ER) modulators have been developed as both tissue-specific ER agonists and antagonists for treating breast cancer and various postmenopausal symptoms in women (15). Since the ligand-activated AhR modulates diverse genes/responses, this receptor is an excellent target for drug development. For example, TCDD inhibits spontaneous 17 β -estradiol (E2)-induced mammary and uterine tumor formation in Sprague-Dawley rats suggesting that TCDD exhibits antiestrogenic activity. Research in our

Correspondence to: Professor Stephen Safe, Department of Veterinary Physiology and Pharmacology, Texas A&M University, 4466 TAMU, College Station, TX 77843-4466, USA
E-mail: ssafe@cvm.tamu.edu

Key words: Ah receptor, SAhRMs, antitumorigenic, antiestrogenic, cancer cells




Figure 1. Structurally diverse compounds that bind the Ah receptor including the SAhRMs 6-MCDF and DIM.

laboratory has focused on studying the mechanisms of inhibitory AhR-ER crosstalk (3,16-18) and developing selective AhR modulators (SAhRMs) for treating breast and endometrial cancers (19,20).

2. Inhibitory AhR-ER α crosstalk: *in vivo*

The antiestrogenic/antitumorigenic activity of TCDD observed in female Sprague-Dawley rats stimulated *in vivo* and *in vitro* studies to determine the specificity of this response (reviewed in refs. 13,16-20). The immature and/or ovariectomized female rat and mouse uterus has been used as a model, and TCDD inhibited several E2-induced uterine responses including progesterone receptor (PR) binding, uterine wet weight, peroxidase activity, *c-fos* and epidermal growth factor receptor (EGFR) mRNA levels, and EGFR binding. Similar results were obtained for the growth of E2-dependent mammary tumors in carcinogen-induced Sprague-Dawley rats and athymic nude mice bearing breast cancer cell xenografts. Recent studies (21) also show that women accidentally exposed to TCDD in Seveso, Italy in 1976 exhibit decreased rates of breast and endometrial cancer, and these observations in humans parallel the effects of TCDD in rodents.

3. Inhibitory AhR-ER α crosstalk: *in vitro*

The interactions of the AhR and ER signaling pathways have been investigated in several ER-positive breast and endometrial cancer cell lines, and these include MCF7, ZR-75 and T47D breast cancer cell lines and Ishikawa, HEC1A and ECC-1 endometrial cancer cells. All of these cell lines express the AhR, and AhR agonists such as TCDD induce CYP1A1 gene expression, a highly characteristic Ah-responsive gene in cell

culture and animal models. In addition, TCDD and related compounds also inhibited E2-induced breast and endometrial cancer cell proliferation (22-25). Subsequent studies have demonstrated that AhR agonists inhibit several E2-induced responses at the gene, protein and reporter gene level using constructs containing E2-responsive gene promoter inserts. For example, in MCF-7 human breast cancer cells, TCDD inhibits E2-induced PR, pS2, cathepsin D mRNA and protein levels, *c-fos* and prolactin mRNA levels, cyclin D1 protein, retinoblastoma (Rb) protein phosphorylation, glucose metabolism, and plasminogen activator activity. A major pathway for AhR-mediated inhibition of E2-induced MCF-7 cell proliferation is linked to the selective inhibition of critical E2-induced cell cycle regulatory proteins such as cyclin D1, Rb phosphorylation and E2F1 (Fig. 2), and these inhibitory responses block E2-induced G₁→S phase cell cycle progression (26).

Inhibitory AhR-ER crosstalk is observed not only in breast cancer cells, but also in E2-responsive endometrial and ovarian cancer cells where TCDD inhibits E2-induced cell proliferation (24,25,27). The mechanisms associated with the effects of AhR agonists on hormone-induced cell proliferation have primarily been investigated in breast cancer cell lines (see below); however, it is likely that interactions between AhR-ER signaling pathways are comparable in breast, endometrial and ovarian cell lines.

4. Mechanisms of AhR-ER crosstalk

Results of initial studies in this laboratory showed that TCDD inhibited E2-induced expression of multiple genes and similar results were observed in transient transfection studies using constructs containing E2-responsive gene promoter inserts. These results suggested that the ligand-bound AhR disrupted




Figure 2. Interactions of E2 and TCDD on cell cycle progression in MCF-7 human breast cancer cells (26).

a promoter- and E2-dependent transcriptionally-active complex. This type of inhibitory crosstalk could occur via several pathways including AhR-dependent induction or inhibition of a critical factor involved in hormone-induced transactivation, direct interaction of the AhR with critical *trans*-acting factors or associated proteins, and interaction of the AhR with critical *cis*-acting elements (Fig. 3). Analysis of the E2-responsive cathepsin D, *c-fos*, pS2 and heat shock protein 27 gene promoters have identified pentanucleotide GCGTG sequences which are required for inhibitory AhR-ER crosstalk (28-32), and these motifs weakly bind the AhR complex and correspond to the core of a dioxin response element (DRE). Inhibitory DREs (iDRE) are strategically located within gene promoters and block formation of a transcriptionally-active complex. For example, binding of the AhR complex to the upstream iDRE in the cathepsin D gene promoter (-175 to -181) disrupts formation of the ER/Sp1 complex which is also formed in the same region of the promoter (-199 to -165). Results of more recent studies demonstrate that several constructs containing E2-responsive gene promoter (e.g. retinoic acid receptor α 1) inserts are also inhibited by AhR agonists in transient transfection studies, and these promoters do not contain functional iDREs. Currently, we are investigating other mechanisms including the role of AhR-activated proteasome-dependent degradation of the ER (33) and sequestration of the ER through direct AhR-ER interactions.

5. Selective AhR modulators (SAhRMs) for treatment of ER-positive breast cancer

The environmental toxicant TCDD has been routinely used as a prototype for investigating AhR-mediated responses including inhibitory AhR-ER interactions in the rodent uterus and mammary tumors and in breast/endometrial cancer cells. Alternate substituted 6-alkyl-1,3,8-trichlorodibenzofurans were initially characterized as AhR antagonists which exhibited low toxicity, and in combination with TCDD, one of these analogs [6-methyl-1,3,8-trichlorodibenzofuran (6-MCDF)] (Fig. 1) inhibited TCDD-induced CYP1A1 gene




Figure 3. Inhibitory AhR-ERu crosstalk. Inhibitory responses are gene-specific and may involve direct interactions with iDREs (28-32), proteasome-dependent degradation of ERu (33), or induction of inhibitory transcription factors (TFs).

expression, immunotoxicity, hepatic porphyria, and cleft palate in mice (34-37). However, 6-MCDF and related compounds were agonists for inhibitory AhR-ER crosstalk in both *in vitro* and *in vivo* models (38-41). For example, 6-MCDF inhibits carcinogen-induced mammary tumor growth in female Sprague-Dawley at doses as low as 50 μ g/kg per day (42,43). Moreover, in ovariectomized female rats of a comparable age, 6-MCDF inhibited tamoxifen-induced estrogenic responses in the uterus (e.g. peroxidase activity, progesterone receptor binding) but did not affect the ER agonist effects of tamoxifen on bone growth (43). These results, coupled with the observed inhibitory AhR-ER crosstalk in endometrial cancer cells suggest that combined therapy with SAhRMs, such as 6-MCDF plus tamoxifen, will be highly effective for treating mammary cancer and also protecting against tamoxifen-induced estrogenic responses in the uterus. This latter interaction is important since long-term treatment with tamoxifen is associated with an increased incidence of endometrial cancer (44). We have also investigated the AhR agonist activities of diindolylmethane (DIM) (Fig. 1) and a series of dihalo- and dialkylDIM analogs (45-47). These compounds bind the AhR and exhibit some of the agonist/antagonist activities observed for 6-MCDF. Moreover, in rodent models for mammary carcinogenesis, many of the DIM compounds were potent inhibitors of mammary tumor growth.

6. SAhRMs for treatment of ER-negative breast cancer

The AhR is expressed in ER-positive and -negative breast cancer cell lines and in human mammary tumors; however, initial studies indicated that the AhR was not functional in ER-negative cell lines and the diagnostic induction of CYP1A1-dependent activity by TCDD was not observed (48,49). This failure to observe induction could be overcome by transient overexpression of ER α (50,51), and a recent study suggested that Ah non-responsiveness in ER-negative MDA-MB-231 cells may be linked to overexpression of heat shock protein 90 which sequesters and inactivates the AhR (52). ER-negative MDA-MB-468 express a functional AhR




Figure 4. Inhibition of PC3 prostate cancer cell growth by different concentrations of DIM.

and TCDD induces CYP1A1 gene expression; moreover, both TCDD and 6-MCDF inhibit MDA-MB-468 cell growth through induction of transforming growth factor α which is growth inhibitory in this cell line (53). Results of ongoing studies also indicate that 6-MCDF inhibits tumor growth in athymic nude mice bearing MCF-7 or MDA-MB-468 cell xenografts. In addition, a more extensive survey of ER-negative breast cancer cells shows that several of these cell lines, including MDA-MB-453, MDA-MB-435, HCC-38 and BT-20 cells, express a functional AhR (i.e. CYP1A1 inducibility by TCDD) and 6-MCDF inhibits cell proliferation. Current studies are further characterizing the growth inhibitory and antitumorigenic activity of 6-MCDF and related SAHRMs using ER-negative breast cancer cells and thereby expanding the potential therapeutic applications of SAHRMs for treating breast cancer.

7. Potential applications of SAHRMs for treating other cancers

The AhR is expressed in cancer cells derived from tumors from multiple tissues; however, the potential applications of SAHRMs for inhibiting growth of these tumors has not been extensively investigated. Research in this laboratory has demonstrated that TCDD and/or 6-MCDF inhibit E2-induced proliferation of E2-responsive PE04 ovarian and Ishikawa/ECC1 endometrial cancer cell lines (24,25,27). Smoking is known to be protective for development of endometrial cancer in women and benzo[a]pyrene, an AhR agonist that is a component of cigarette smoke and other combustion products also inhibits E2-induced proliferation of Ishikawa endometrial cancer cells (25,54,55). Recent studies show that AhR agonists also block androgen receptor (AR) signaling including testosterone-induced prostate-specific antigen (protein and mRNA) (56,57). We have also investigated inhibitory AhR-AR interactions in prostate cancer cells and the results in Fig. 4 demonstrate that DIM inhibits proliferation of PC-3 prostate cancer cells maintained in 0

and 1% serum. These results suggest that SAHRMs may also be useful for inhibiting prostate and possibly other cancers, and the applications and mechanisms of action of these compounds are currently being investigated.

8. Summary

Ligand-activated receptors are ideal targets for developing tissue-selective modulators for treating different diseases. The AhR is widely expressed in mammalian tissues and tumors, and it is clear from studies on TCDD that multiple genes/responses are mediated through the AhR, and these include inhibition or enhancement of immune responses, reproductive toxicity, a wasting syndrome, carcinogenic and anticarcinogenic responses, proteasome activation, and tissue-specific up- or downregulation of several genes. Our research has focused on development of tissue-selective SAHRMs for treatment of mammary cancer and it is possible that SAHRMs may also inhibit growth of tumors in other tissues, and these are currently being investigated.

Acknowledgements

The financial assistance of the National Institutes of Health (ES09106, CA64081 and ES04176), DOD-US Army Medical Research and Materiel Command Grant (17-02-1-0147), Avax Technologies (Kansas City), and the Texas Agricultural Experiment Station is gratefully acknowledged. S.S. is a Sid Kyle Professor of Toxicology.

References

- Poland A, Glover E and Kende AS: Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin by hepatic cytosol: evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. *J Biol Chem* 251: 4936-4946, 1976.
- Poland A and Knutson JC: 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin and related halogenated aromatic hydrocarbons. Examinations of the mechanism of toxicity. *Annu Rev Pharmacol Toxicol* 22: 517-554, 1982.
- Safe S: Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin and related compounds. *Pharmacol Ther* 67: 247-281, 1995.
- Wilson CL and Safe S: Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses. *Toxicol Pathol* 26: 657-671, 1998.
- Swanson HI and Bradfield CA: The Ah-receptor: genetics, structure and function. *Pharmacogenetics* 3: 213-223, 1993.
- Whitlock JP Jr: Mechanistic aspects of dioxin action. *Chem Res Toxicol* 6: 754-763, 1993.
- Denison MS, Seidel SD, Rogers WJ, Ziccardi M, Winter GM and Heath-Pagliuso S: Natural and synthetic ligands for the Ah receptor. In: *Molecular Biology Approaches to Toxicology*. Puga A and Kendall RJ (eds.) Taylor and Francis, London, pp3-33, 1998.
- Gradelet S, Astorg P, Pineau T, Canivenc MC, Siess MH, Leclerc J and Lesca P: Ah receptor-dependent CYP1A induction by two carotenoids, canthaxanthin and β -apo-8'-carotenal, with no affinity for the TCDD binding site. *Biochem Pharmacol* 54: 307-315, 1997.
- Bjeldanes LF, Kim JY, Grose KR, Bartholomew JC and Bradfield CA: Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol *in vitro* and *in vivo* - comparisons with 2,3,7,8-tetrachlorodibenzo-*p*-dioxin. *Proc Natl Acad Sci USA* 88: 9543-9547, 1991.
- Chen I, Safe S and Bjeldanes L: Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. *Biochem Pharmacol* 51: 1069-1076, 1996.

11. Quadri SA, Qadri AN, Hahn ME, Mann KK and Sherr DH: The bioflavonoid galangin blocks aryl hydrocarbon receptor activation and polycyclic aromatic hydrocarbon-induced pre-B cell apoptosis. *Mol Pharmacol* 58: 515-525, 2000.
12. Savouret JF, Antenos M, Quesne M, Xu J, Milgrom E and Casper RF: 7-Ketocholesterol is an endogenous modulator for the arylhydrocarbon receptor. *J Biol Chem* 276: 3054-3059, 2001.
13. Chun YJ, Ryu SY, Jeong TC and Kim MY: Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. *Drug Metab Dispos* 29: 389-393, 2001.
14. Sinal CJ and Bend JR: Aryl hydrocarbon receptor-dependent induction of Cyp1a1 by bilirubin in mouse hepatoma Hepa 1c1c7 cells. *Mol Pharmacol* 52: 590-599, 1997.
15. Fuqua SA, Russo J, Shackney SE and Stearns ME: Estrogen, estrogen receptors and selective estrogen receptor modulators in human breast cancer. *J Women's Cancer* 2: 21-32, 2000.
16. Zacharewski T and Safe S: Antiestrogenic activity of TCDD and related compounds. In: *Reproductive and Developmental Toxicology*. Korach KS (ed.) Marcel Dekker, Inc., New York, pp431-448, 1998.
17. Porter W and Safe S: Estrogenic and antiestrogenic compounds. In: *Molecular Biology Approaches to Toxicology*. Puga A and Wallace KB (eds.) Techbooks, Fairfax, VA, pp267-283, 1998.
18. Safe S: 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) and related environmental antiestrogens: characterization and mechanism of action. In: *Endocrine Disruptors*. Naz RK (ed.) CRC Press, Boca Raton, FL, pp187-221, 1999.
19. Safe S, Qin C and McDougal A: Development of selective aryl hydrocarbon receptor modulators (SARMs) for treatment of breast cancer. *Expert Opin Invest Drugs* 8: 1385-1396, 1999.
20. Safe S, McDougal A, Gupta MS and Ramamoorthy K: Selective Ah receptor modulators (SAHRMs): progress towards development of a new class of inhibitors of breast cancer growth. *J Women's Cancer* 3: 37-45, 2001.
21. Bertazzi PA, Consonni D, Bachetti S, Rubagotti M, Baccarelli A, Zocchetti C and Pesatori AC: Health effects of dioxin exposure: a 20-year mortality study. *Am J Epidemiol* 153: 1031-1044, 2001.
22. Biegel L and Safe S: Effects of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) on cell growth and the secretion of the estrogen-induced 34-, 52- and 160-kDa proteins in human breast cancer cells. *J Steroid Biochem Mol Biol* 37: 725-732, 1990.
23. Fernandez P and Safe S: Growth inhibitory and antimetastatic activity of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) in T47D human breast cancer cells. *Toxicol Lett* 61: 185-197, 1992.
24. Castro-Rivera E, Wormke M and Safe S: Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells. *Mol Cell Endocrinol* 150: 11-21, 1999.
25. Wormke M, Castro-Rivera E, Chen I and Safe S: Estrogen and aryl hydrocarbon receptor expression and crosstalk in human Ishikawa endometrial cancer cells. *J Steroid Biochem Mol Biol* 72: 197-207, 2000.
26. Wang W, Smith R and Safe S: Aryl hydrocarbon receptor-mediated antiestrogenicity in MCF-7 cells: modulation of hormone-induced cell cycle enzymes. *Arch Biochem Biophys* 356: 239-248, 1998.
27. Rowlands C, Krishnan V, Wang X, Santostefano M, Safe S, Miller WR and Langdon S: Characterization of the aryl hydrocarbon (Ah) receptor and Ah-responsiveness in human ovarian carcinoma cell lines. *Cancer Res* 53: 1802-1807, 1993.
28. Krishnan V, Porter W, Santostefano M, Wang X and Safe S: Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) in MCF-7 cells. *Mol Cell Biol* 15: 6710-6719, 1995.
29. Duan R, Porter W, Samudio I, Vyhldal C, Kladde M and Safe S: Transcriptional activation of c-fos protooncogene by 17 β -estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition. *Mol Endocrinol* 13: 1511-1521, 1999.
30. Moore M, Wang X, Lu YF, Wormke M, Craig A, Gerlach JH, Burghardt R, Barhouni R and Safe S: Benzo[a]pyrene-resistant MCF-7 human breast cancer cells. A unique aryl hydrocarbon nonresponsive clone. *J Biol Chem* 269: 11751-11759, 1994.
31. Gillesby B, Santostefano M, Porter W, Wu ZF, Safe S and Zacharewski T: Identification of a motif within the 5'-regulatory region on pS2 which is responsible for Apl binding and TCDD-mediated suppression. *Biochemistry* 36: 6080-6089, 1997.
32. Porter W, Wang F, Duan R, Qin C, Castro-Rivera E and Safe S: Transcriptional activation of heat shock protein 27 gene expression by 17 β -estradiol and modulation by antiestrogens and aryl hydrocarbon receptor agonists: estrogenic activity of ICI 164,384. *J Mol Endocrinol* 26: 31-42, 2001.
33. Harris M, Zacharewski T, Astroff B and Safe S: Partial antagonism of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-mediated induction of aryl hydrocarbon hydroxylase by 6-methyl-1,3,8-trichlorodibenzofuran: mechanistic studies. *Mol Pharmacol* 35: 729-735, 1989.
34. Wormke M, Stoner M, Saville B and Safe S: Crosstalk between estrogen receptor α and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. *FEBS Lett* 478: 109-112, 2000.
35. Astroff B, Zacharewski T, Safe S, Ariotto MP, Parkinson A, Thomas P and Levin W: 6-Methyl-1,3,8-trichlorodibenzofuran as a 2,3,7,8-tetrachlorodibenzo-*p*-dioxin antagonist: inhibition of the induction of rat cytochrome P-450 isozymes and related monooxygenase activities. *Mol Pharmacol* 33: 231-236, 1988.
36. Bannister R, Biegel L, Davis D, Astroff B and Safe S: 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as a 2,3,7,8-tetrachlorodibenzo-*p*-dioxin antagonist in C57BL/6 mice. *Toxicology* 54: 139-150, 1989.
37. Yao C and Safe S: 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin-induced porphyria in genetically inbred mice: partial antagonism and mechanistic studies. *Toxicol Appl Pharmacol* 100: 208-216, 1989.
38. Astroff B and Safe S: Comparative antiestrogenic activities of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin and 6-methyl-1,3,8-trichlorodibenzofuran in the female rat. *Toxicol Appl Pharmacol* 95: 435-443, 1988.
39. Astroff B and Safe S: 6-Alkyl-1,3,8-trichlorodibenzofurans as antiestrogens in female Sprague-Dawley rats. *Toxicology* 69: 187-197, 1991.
40. Zacharewski T, Harris M, Biegel L, Morrison V, Merchant M and Safe S: 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: evidence for the role of the Ah receptor. *Toxicol Appl Pharmacol* 13: 311-318, 1992.
41. Dickerson R, Howie-Keller L and Safe S: Alkyl polychlorinated dibenzofurans and related compounds as antiestrogens in the female rat uterus: structure-activity studies. *Toxicol Appl Pharmacol* 135: 287-298, 1995.
42. McDougal A, Wilson C and Safe S: Inhibition of 7,12-dimethylbenz[*a*]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. *Cancer Lett* 120: 53-63, 1997.
43. McDougal A: *Aromatic Hydrocarbon Receptor-Based Antiestrogens as Treatments for Breast Cancer*. Texas A&M University. Thesis/Dissertation, 2000.
44. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA and Ford L: Tamoxifen therapy for breast cancer and endometrial cancer risk. *J Natl Cancer Inst* 91: 1654-1662, 1999.
45. Chen I, McDougal A, Wang F and Safe S: Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolymethane. *Carcinogenesis* 19: 1631-1639, 1998.
46. McDougal A, Sethi-Gupta M, Ramamoorthy K, Sun G and Safe S: Inhibition of carcinogen-induced rat mammary tumor growth and other estrogen-dependent responses by symmetrical dihalo-substituted analogs of diindolymethane. *Cancer Lett* 151: 169-179, 2000.
47. McDougal A, Gupta MS, Morrow D, Ramamoorthy K, Lee Y-E and Safe S: Methyl-substituted diindolymethanes as inhibitors of estrogen-induced growth of T47D cells and mammary tumors in rats. *Breast Cancer Res Treat* 66: 147-157, 2001.
48. Vickers PJ, Dufresne MJ and Cowan KH: Relation between cytochrome P4501A1 expression and estrogen receptor content of human breast cancer cells. *Mol Endocrinol* 3: 157-164, 1989.
49. Wang X, Thomsen JS, Santostefano M, Rosengren R, Safe S and Perdew GH: Comparative properties of the nuclear Ah receptor complex from several human cell lines. *Eur J Pharmacol* 293: 191-205, 1995.
50. Mattson MP and Kater SB: Isolated hippocampal neurons in cryopreserved long-term cultures: development of neuroarchitecture and sensitivity to NMDA. *Int J Dev Neurosci* 6: 439-452, 1988.
51. Wang WL, Thomsen JS, Porter W, Moore M and Safe S: Effect of transient expression of the estrogen receptor on constitutive and inducible CYP1A1 in Hs578T human breast cancer cells. *Br J Cancer* 73: 316-322, 1996.

52. Caruso JA, Laird DW and Batist G: Role of HSP90 in mediating cross-talk between the estrogen receptor and the Ah receptor signal transduction pathways. *Biochem Pharmacol* 58: 1395-1403, 1999.
53. Wang W, Porter W, Burghardt R and Safe S: Mechanism of inhibition of MDA-MB-468 breast cancer cell growth by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin. *Carcinogenesis* 18: 925-933, 1997.
54. Lesko SM, Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Strom B, Schottenfeld D, Rosenschein NB, Knapp RC, Lewis J and Shapiro S: Cigarette smoking and the risk of endometrial cancer. *N Engl J Med* 313: 593-596, 1985.
55. Baron JA, La Vecchia C and Levi F: The antiestrogenic effect of cigarette smoking in women. *Am J Obstet Gynecol* 162: 502-514, 1990.
56. Jana NR, Sarkar S, Ishizuka M, Yonemoto J, Tohyama C and Sone H: Cross-talk between 2,3,7,8-tetrachlorodibenzo-*p*-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. *Biochem Biophys Res Commun* 256: 462-468, 1999.
57. Jana NR, Sarkar S, Ishizuka M, Yonemoto J, Tohyama C and Sone H: Comparative effects of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin on MCF-7, RL95-2, and LNCaP cells: role of target steroid hormones in cellular responsiveness to CYP1A1 induction. *Mol Cell Biol Res Commun* 4: 174-180, 2000.

Society of Toxicology
41ST ANNUAL MEETING

Toxicology 2002 Call for Paper Confirmation

Derek Morrow

First Name : Derek
Last Name : Morrow
Job Title : Graduate Research Assistant
Organization : Texas A&M University
Address : Veterinary Physiology & Pharmacology
City : College Station
State/Prov. : TX
ZIP/Postal Code : 77843-4466
Country : United States
Phone Number : 979-845-9832
Fax Number : 979-862-4929
E-mail Address : ssafe@cvm.tamu.edu

Thank you for submitting your abstract COMPARATIVE ARYL HYDROCARBON RECEPTOR-HORMO
Late Breaking Abstract site. Abstracts will be reviewed and you will
receive acceptance notification, as well as presentation information
shortly after February 15.

We look forward to your participation in the 2002 SOT Annual Meeting.

SOT Headquarters
Date: February 15, 2002

© Toxicology 2002 - All Rights Reserved

COMPARATIVE ARYL HYDROCARBON RECEPTOR-HORMONE RECEPTOR CROSSTALK IN BREAST AND PROSTATE CANCER CELLS. D Morrow, A McDougal and S Safe. Department of Veterinary Physiology & Pharmacology, Texas A&M University, College Station, TX, USA.

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) is a ligand for the aryl hydrocarbon receptor (AhR) and inhibits growth of both breast (T47D) and prostate (LNCaP and 22RV1) cancer cells in culture. One mechanism for TCDD-induced inhibitory activity in breast cancer cells involves activation of proteasome-dependent degradation of estrogen receptor α (ER α). This study investigated the comparative effects of TCDD and steroid hormones on receptor proteins in breast and prostate cancer cells. T47D, LNCaP and 22RV1 cells express the androgen receptor (AR) and, after treatment with 10 nM dihydrotestosterone (DHT) for 24 h, there was a significant 4- to 6-fold upregulation of immunoreactive AR protein, and this increase was observed within 1 to 3 h after treatment in all three cell lines. In contrast, 17 β -estradiol (E2) decreased AR levels in T47D cells, whereas in prostate cancer cells, AR levels were slightly elevated by E2. TCDD induces proteasome-dependent degradation of ER α in breast cancer cells; however, after treatment with 10 nM TCDD for up to 24 h, only minimal changes in immunoreactive AR protein were observed in T47D breast and 22RV1 prostate cells. Combined treatment with DHT plus TCDD resulted in some decreases in AR protein in 22RV1 cells (compared to treatment with DHT alone), whereas TCDD did not alter upregulation of AR protein by DHT in T47D cells. Thus, the effects of TCDD on AR and other hormone receptors in prostate and breast cancer cells are dependent on cell context, and current studies are focused on the mechanisms of AhR-hormone receptor crosstalk in both breast and prostate cancer cell lines (Supported by DOD-USAMRMC 17-02-1-0147 and NIH ES09106).

	1	2	3
Topic #s	41	33	18
Keywords	Hormone receptors	TCDD	crosstalk